Published Date:2020-11-11 Original Link:https://www.onenessbio.com/en/news_detail72_1.htm No 1 Date of announcement 2020/11/11 Time of announcement 18:25:13 Subject Oral presentation by Oneness Biotech at EWMA 2020 virtual conference on ON101 global Phase 3 MRCT results. To which item it meets paragraph 12 Date of events 2020/11/11 Statement 1.Date of institutional investor conference: 2020/11/18 2.Time of institutional...Read More
Published Date:2020-11-05 Original Link:https://www.onenessbio.com/en/news_detail71_1.htm No 1 Date of announcement 2020/11/05 Time of announcement 19:15:48 Subject Oneness submits an IND to TFDA on a phase II clinical trial of FB704A, a mAb developed from its own platform, for treating severe neutrophilic asthma. To which item it meets paragraph 10 Date of events 2020/11/05 Statement...Read More
Published Date:2020-11-02 Original Link:https://www.onenessbio.com/en/news_detail70_1.htm No 1 Date of announcement 2020/11/02 Time of announcement 21:01:47 Subject Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2020/11/02 Statement 1.Date of occurrence of the...Read More
Published Date:2020-10-28 Original Link:https://www.onenessbio.com/en/news_detail68_1.htm No 1 Date of announcement 2020/10/28 Time of announcement 01:22:39 Subject Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2020/10/28 Statement 1.Date of occurrence of the...Read More
